1
|
Carpenter J, Falkson C, Nabell L, Santos JDL, Krontiras H, Bland K, Li Y, Bae S. P121 Primary Chemotherapy with Bevacizumab for Locally Advanced Triple Negative Breast Cancer. Breast 2023. [DOI: 10.1016/s0960-9776(23)00238-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/17/2023] Open
|
2
|
Clark C, della Manna D, Nabell L, Willey C, Bonner J, Dobelbower M, Spencer S, Yang E. Immune and Tumor Genome Signatures Associated with Response to Radiotherapy and Chk-1 Inhibition in a Phase 1b Clinical Trial for Patients with Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.12.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Lenzie A, Hoyle J, Yang E, Spencer S, Willey C, Bonner J, Dobelbower M, Snider J, McCammon S, Carroll W, Nabell L, Bhatia S, McDonald A. Pain, Weight Loss, and Quality of Life in a Supportive Care Trial for Patients With Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Mukherjee A, Griffin R, Lenneman C, Lewis C, Nabell L, Shrestha S. Racial disparities in prevalence of cardiovascular disease risk factors in head and neck cancer patients. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Other. Main funding source(s): American Heart Association Pre-doctoral Fellowship
Background
Cancer patients and survivors have higher burden of cardiovascular diseases than the age-adjusted general population. However, evidence on distribution of cardiovascular disease risk factors in cancer patients is limited.
Purpose
Our aim was to assess if racial disparities exist in prevalence of cardiovascular disease risk factors in head and neck cancer patients.
Methods
In this clinical cohort, we included 2299 head neck squamous cell carcinoma (HNSCC) patients diagnosed between 2012-2018 at a National Cancer Institute-designated Cancer Center. We used a combination of ICD-9/10 codes, medication use and pharmacy records from electronic medical records data, to identify cardiovascular disease risk factors (hypertension, dyslipidemia and diabetes mellitus). We reported prevalence of cardiovascular disease risk factors at and one year-post HNSCC diagnosis, by race, using Chi-square or Wilcoxon test, as appropriate.
Results
Black HNSCC patients were diagnosed at a slightly younger age (median: 60.0 vs 62.0 years, p-value 0.0745), had a higher proportion of males (p-value 0.0221) and advanced cancer stage at diagnosis (p-value 0.0033), than white HNSCC patients. At diagnosis, 32.63% of black HNSCC patients had hypertension and 34.44% had at least one cardiovascular disease risk factor, compared to 24.59% and 27.74% in whites, respectively (p-values 0.0020 and 0.0127, respectively). At one-year post HNSCC diagnosis, 84.73% of all HNSCC patients had at least one cardiovascular disease risk factor. No statistically significant racial differences were observed for hypertension and diabetes mellitus at one-year post HNSCC diagnosis, however, 37.74% of white HNSCC patients had dyslipidemia compared to 27.49% black patients (p-value 0.003).
Conclusion
Higher prevalence of hypertension and advanced cancer stage at HNSCC diagnosis in black patients highlights issues of racial disparity and unequal access to care. High prevalence of cardiovascular disease risk factors at one-year post HNSCC diagnosis and increase in dyslipidemia in white patients emphasizes the impact of therapeutic agents and need for routine personalized monitoring of cardiovascular disease risk factors and cardiovascular disease preventive services in high risk HNSCC patients.
Collapse
Affiliation(s)
- A Mukherjee
- University of Alabama at Birmingham, Birmingham, United States of America
| | - R Griffin
- University of Alabama at Birmingham, Birmingham, United States of America
| | - C Lenneman
- University of Alabama at Birmingham, Birmingham, United States of America
| | - C Lewis
- University of Alabama at Birmingham, Birmingham, United States of America
| | - L Nabell
- University of Alabama at Birmingham, Birmingham, United States of America
| | - S Shrestha
- University of Alabama at Birmingham, Birmingham, United States of America
| |
Collapse
|
5
|
Strickler S, Yang E, Spencer S, Willey C, Bonner J, Dobelbower M, Nabell L, McCammon S, Bhatia S, Carroll W, McDonald A. Effect of Protocol-based Pain Management on Patient Reported Pain During Radiation for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Adkins D, Cohen E, Nabell L, Zandberg D, Old M, Cognetti D, Blair D, Wei X, Wells A, Patel A, Foy T, Hege K, Ferris R. A Phase 1b Presurgical Window Study to Evaluate Immune Biomarker Modulation in Response to Motolimod and Nivolumab in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Yang E, Deutsch E, Mehmet A, Fayette J, Nabell L, Spencer S, Dobelbower M, Willey C, Bonner J, Wang X, Lin A, William W. A phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Hollebecque A, Assouline S, Samaniego F, You B, Foss F, Prica A, Gordon SW, Webster M, Dyer MJS, El-Sharkawi D, Shapiro GI, Nabell L, Blagden SP, Lister J, Ulahannan SV, Sun Y, Chan D, Ferraldeschi R, Mita M. Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma. Mol Cancer Ther 2019. [DOI: 10.1158/1535-7163.targ-19-a072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: ASTX660 is an oral, novel nonpeptidomimetic, small-molecule antagonist of cellular/X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). ASTX660 is currently being evaluated in a first-in-human phase 1–2 study in patients (pts) with advanced solid tumors or lymphoma (ClinicalTrials.gov NCT02503423). In the ongoing phase 2, ASTX660 has demonstrated preliminary evidence of clinical activity in the relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) cohorts (Mehta et al, presented at the EHA Conference 2019, abs PS1073). Here, we report overall efficacy and safety data from the solid tumors (head and neck squamous cell carcinoma [HNSCC]; cervical carcinoma and other solid tumors) and lymphoma (diffuse large B-cell lymphoma [DLBCL], PTCL, CTCL,) phase 2 cohorts. Methods: Pts received treatment with ASTX660 orally at the RP2D 180mg/day on days 1 to 7, and 15 to 22 in a 28-day cycle. In the first stage 14 evaluable pts were enrolled in each of the 6 phase 2 cohorts with the option to expand the cohort if activity was observed. The primary endpoint was response rate as assessed by the investigator according to the Lugano criteria (DLBCL and PTCL), Global Assessment (CTCL), or RECIST 1.1 (solid tumors). Adverse events (AEs) were assessed per CTCAE V4.03. Results: As of June 4, 2019, a total of 107 pts have received ASTX660 in the solid tumors and lymphoma phase 2 cohorts (HNSCC n=14; DLBCL n=16; PTCL n=26; CTCL n=23; cervical carcinoma n=14; other solid tumors n= 14). Median age (range) was 61 (23-84) years and median number (range) of prior anticancer regimens was 3 (0-12). Among all pts, the most common related AEs of any grade (≥ 10%) were rash (35%), lipase elevation (34%), amylase elevation (29%), diarrhea (14%), fatigue (14%), AST elevation (13%), nausea (13%), and anemia (11%). Related AEs ≥ Grade 3 occurring in ≥ 5% of pts were rash (18%), lipase elevation (16%) and amylase elevation (9%). As of 4 June 2019, 86 pts (80%) discontinued study treatment: 64 (60%) due to progressive disease, 13 (12%) due to AE, 4 (4%) due to death, 4 (4%) due to withdrawal by participant and 1 (1%) for investigator’s decision. At the time of analysis, the ORR was 36% in the PTCL cohort and 15% in the CTCL cohort. One PR was reported in a pt with metastatic melanoma after 12 cycles of treatment. No objective responses were reported in the HNSCC, DLBCL or cervical cohorts. Accrual in the PTCL and CTCL continues; updated efficacy and safety data will be presented at the meeting. Conclusion: In the phase 2 part of the study ASTX660 monotherapy has demonstrated a manageable safety profile and encouraging activity in PTCL and CTCL warranting cohort expansion. Future plans include evaluation of ASXT660 both as mono- or combination therapy in selected malignancies.
Citation Format: Antoine Hollebecque, Sarit Assouline, Felipe Samaniego, Benoit You, Francine Foss, Anca Prica, Sarah W. Gordon, Marc Webster, Martin JS. Dyer, Dima El-Sharkawi, Geoffrey I. Shapiro, Lisa Nabell, Sarah P. Blagden, John Lister, Susanna V. Ulahannan, Yijun Sun, Danna Chan, Roberta Ferraldeschi, Monica Mita. Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A072. doi:10.1158/1535-7163.TARG-19-A072
Collapse
Affiliation(s)
| | | | | | | | | | - Anca Prica
- 6Princess Margaret Cancer Centre, Toronto, ON
| | | | | | - Martin JS. Dyer
- 9Ernest and Helen Scott Haematological Research Institute University of Leicester, Leicester
| | | | | | - Lisa Nabell
- 12University of Alabama at Birmingham, Birmingham, AL
| | - Sarah P. Blagden
- 13Churchill Hospital, Oxford University Hospital NHS Trust, Oxford
| | - John Lister
- 14Allegheny Health Network Cancer Institute, Pittsburgh, PA
| | - Susanna V. Ulahannan
- 15Stephenson Cancer Center, OUHSC and Sarah Cannon Research Institute, Oklahoma City, OK
| | - Yijun Sun
- 16Astex Pharmaceuticals, Inc., Pleasanton, CA
| | - Danna Chan
- 16Astex Pharmaceuticals, Inc., Pleasanton, CA
| | | | | |
Collapse
|
9
|
Cohen E, Algazi A, Laux D, Wong D, Amin A, Nabell L, Chisamore M, Gamelin E, Janssen R, Bishnoi S. Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Siu L, Even C, Mesía R, Daste A, Krauss J, Saba N, Nabell L, Ready N, Garcia I, Kotecki N, Zandberg D, Gilbert J, Mehanna H, Jarkowski A, Melillo G, Armstrong J, Fayette J. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
11
|
Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ. Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors. Ann Oncol 2015; 26:1481-7. [PMID: 25899782 DOI: 10.1093/annonc/mdv196] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Accepted: 04/15/2015] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND The use of Escherichia coli purine nucleoside phosphorylase (PNP) to activate fludarabine has demonstrated safety and antitumor activity during preclinical analysis and has been approved for clinical investigation. PATIENTS AND METHODS A first-in-human phase I clinical trial (NCT 01310179; IND 14271) was initiated to evaluate safety and efficacy of an intratumoral injection of adenoviral vector expressing E. coli PNP in combination with intravenous fludarabine for the treatment of solid tumors. The study was designed with escalating doses of fludarabine in the first three cohorts (15, 45, and 75 mg/m(2)) and escalating virus in the fourth (10(11)-10(12) viral particles, VP). RESULTS All 12 study subjects completed therapy without dose-limiting toxicity. Tumor size change from baseline to final measurement demonstrated a dose-dependent response, with 5 of 6 patients in cohorts 3 and 4 achieving significant tumor regression compared with 0 responsive subjects in cohorts 1 and 2. The overall adverse event rate was not dose-dependent. Most common adverse events included pain at the viral injection site (92%), drainage/itching/burning (50%), fatigue (50%), and fever/chills/influenza-like symptoms (42%). Analysis of serum confirmed the lack of systemic exposure to fluoroadenine. Antibody response to adenovirus was detected in two patients, suggesting that neutralizing immune response is not a barrier to efficacy. CONCLUSIONS This first-in-human clinical trial found that localized generation of fluoroadenine within tumor tissues using E. coli PNP and fludarabine is safe and effective. The pronounced effect on tumor volume after a single treatment cycle suggests that phase II studies are warranted. CLINICALTRIALSGOV IDENTIFIER NCT01310179.
Collapse
Affiliation(s)
- E L Rosenthal
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | - T K Chung
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | | | - P W Allan
- Southern Research Institute, Birmingham
| | - L Clemons
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | - D Lowman
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | - J Hong
- Department of Cellular, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham
| | - F R Hunt
- PNP Therapeutics, Inc., Birmingham
| | - J Richman
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | - R M Conry
- Department of Medicine, University of Alabama at Birmingham, Birmingham
| | - K Mannion
- Department of Otolaryngology Head and Neck Surgery, Vanderbilt University, Nashville, USA
| | - W R Carroll
- Department of Surgery, University of Alabama at Birmingham, Birmingham
| | - L Nabell
- Department of Medicine, University of Alabama at Birmingham, Birmingham
| | | |
Collapse
|
12
|
Forero A, DeLos Santos J, Bowen K, Jones C, Varley KE, Nabell L, Carpenter JT, Falkson CI, Krontiras H, Caterinicchia V, O'Malley J, Li Y, LoBuglio AF, Myers R, Saleh MN. Abstract P1-15-02: Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Vascular endothelial growth factor overexpression has been associated with resistance to anti-estrogen therapy (Cancer Res 2008; 68: 6232); our preclinical data showed that anti-VEGF therapy reverse resistance to estrogen therapy. We postulated that anti-VEGF therapy would enhance anti-estrogen therapy and thus designed a pilot study to assess the feasibility and efficacy of neoadjuvant letrozole and bevacizumab in post-menopausal women with stage II/III, ER/PR positive breast cancer.
Patients and Methods: Eligible patients were treated with a neo-adjuvant regimen of letrozole, 2.5 mg/day (PO) and bevacizumab 15 mg/kg every 3 weeks (IV) for a total of 24 weeks prior to surgical treatment of their breast cancer. Patients were followed for toxicity at three week intervals and for tumor assessment at 6 week intervals. Research tumor biopsies were taken before and 6 weeks after initiation of therapy. The primary endpoint was pathological complete remission (pCR). Patients with inflammatory breast cancer were excluded.
Results: Twenty six patients were enrolled and 25 were treated (one patient had a TIA the day before initiation of therapy). The regimen was well tolerated with 2 patients taken off-study due to uncontrolled hypertension. Objective clinical response occurred in 68% of the patients (17/25), 16% with CR and 52% with partial response (PR). Sixteen percent of the patients (4/25) had clinical stable disease (SD) and 2 patients progressed (PD) while on therapy. Three patients had pCR and 1 patient had microscopic residual tumor cells in the LNs but not in the breast (pCR 16%). Thirty two percent of the patients attained stage 0 or 1 status. None of the pCR patients received adjuvant chemotherapy and none have relapsed after a median follow-up of 6.1 years (range, 5.8+ to 7.5+). Eight of the 13 patients with PR did not receive chemotherapy and only one relapsed with a median follow-up of 6.2 years (range, 3.7 to 7.7+). At a median follow-up of 6.4 years, 88% of the patients have not relapsed and 12% relapsed (1 PD [basal-like], 1 PR [Luminal B], 1 SD [HER2] relapsed at 1.7, 4, and 6.8 years respectively). Of the 17 patients with CR and PR, only 1 has relapsed (6%). Next Generation Sequencing Analysis and evaluation of markers of proliferation/apoptosis are underway.
Conclusion: Combination neoadjuvant therapy with letrozole and bevacizumab was well tolerated and resulted in an impressive pCR of 16%. At a median of 6.4 years, the relapse free survival is 88% for all comers and 94% for responding patients (Luminal A and B). Full correlation of clinical and genomic/biomarker analysis will be presented at the time of the meeting. This encouraging data has led The Breast Cancer Translational Research Consortium to complete a randomized phase II trial (TBCRC002) of letrozole ± bevacizumab in this patient population.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-15-02.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - J DeLos Santos
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - K Bowen
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - C Jones
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - KE Varley
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - L Nabell
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - JT Carpenter
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - CI Falkson
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - H Krontiras
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - V Caterinicchia
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - J O'Malley
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - Y Li
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - AF LoBuglio
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - R Myers
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| | - MN Saleh
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA; HudsonAlpha Institute for Biotechnology, Huntsville, AL
| |
Collapse
|
13
|
Gucalp A, Tolaney S, Isakoff SJ, Ingle J, Liu MC, Carey L, Blackwell KL, Rugo H, Nabell L, Forero A, Stearns V, Momen L, Gonzalez J, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA. Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-05-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Our group and others have identified a subset of ER/PR(−) breast cancers characterized by expression of the androgen receptor (AR) and androgen-dependent growth (Doane 2006). We conducted a proof-of-concept multicenter phase II study to test the efficacy of the AR-antagonist, bicalutamide for the treatment of AR(+) ER/PR(−) MBC (NCT00468715). Results of the primary endpoint, clinical benefit rate (CBR), were presented at ASCO (Gucalp 2012). Data for the impact of bicalutamide on circulating hormone levels in women are limited. Elevations in serum testosterone (T) and estradiol (E) have been observed for men treated with bicalutamide. We hypothesized comparable patterns of change in circulating endocrine markers in response to bicalutamide for women with MBC.
Methods: Patients (pts) with AR(+) (IHC ≥10%), ER/PR(−) (IHC <10%) MBC were eligible for treatment (tx) if ECOG performance status ≤2 and normal organ function regardless of menopausal status. There was no limit to prior tx except prior trastuzumab required if HER2(+). Tx consisted of bicalutamide 150mg orally daily in 28-day cycles (C). Toxicity assessed q4 weeks, response q12wks. Primary endpoint was CBR. Peripheral blood was collected for total and free T, E and sex hormone binding globulin (SHBG) at baseline, start of C2 (C2) and at end of study (EOS). Standard institutional assays were used. A Wilcoxon signed-rank test was done to compare baseline to C2 and EOS values.
Results: 26 patients with AR(+) ER/PR(−) MBC were treated on study. Evaluable number (n) of pts at baseline, C2 and EOS are 26, 26 and 19 respectively. Two pts remain on study. Menopausal status: pre=2, post=24. Baseline median total and free T and estradiol were consistent with expected norms, however a wide range was observed (Table). There were no significant differences observed for median free T, total T, E or SHBG between baseline and C2 or baseline and EOS. Changes in hormone levels could not be stratified by menopausal status or response to bicalutamide given small sample size. Given the wide range of baseline values, we examined the percent change for each endocrine biomarker from baseline to C2 and EOS. As shown in the Table, there was no difference in median percent change observed across time points for each biomarker.
Conclusions: No discernible patterns of change in T, E or SHBG were observed in response to bicalutamide therapy when given to women for the treatment of AR(+), ER/PR(−) MBC. These circulating hormones require further evaluation for use as a pharmacodynamic marker.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-05-02.
Collapse
Affiliation(s)
- A Gucalp
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - S Tolaney
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - SJ Isakoff
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - J Ingle
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - MC Liu
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Carey
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - KL Blackwell
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - H Rugo
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Nabell
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - A Forero
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - V Stearns
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - L Momen
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - J Gonzalez
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - A Akhtar
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - DD Giri
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - S Patil
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - KN Feigin
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - CA Hudis
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| | - TA Traina
- Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
| |
Collapse
|
14
|
Caudell JJ, Spencer S, Meredith R, Nabell L, Bonner JA. Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Nimmagadda S, Nabell L, Carpenter JT, Falkson CI, Krontiras H, De Los Santos JF, Urist MM, Bland KI, LoBuglio AF, Li Y, Forero-Torres A. Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Gucalp A, Tolaney SM, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell KL, Rugo HS, Nabell L, Abbruzzi A, Gonzalez J, Giri DD, Patil S, Feigin K, D'Andrea G, Theodoulou M, Drullinsky P, Sklarin NT, Hudis C, Traina TA. TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps122] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Borate U, Steciuk M, Alexander K, Lynch J, Nabell L, Reddy V, Foran JM. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may overcome adverse prognosis in patients with diffuse large B-cell lymphoma (DLBCL) with an activated B-cell (ABC) molecular profile. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18522] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Forero A, Saleh M, Galleshaw J, Jones C, Nabell L, Carpenter J, Falkson C, Krontiras H, Urist M, Bland K, De Los Santos J, Meredith R, Caterinicchia V, Bernreuter W, O'Malley J, Yufeng L, LoBuglio A. Abstract P1-12-04: Long Term Follow-Up of a Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-12-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Overexpression of vascular endothelial growth factor (VEGF) in breast cancer tumors has been associated with resistance to anti-estrogen adjuvant therapy. We designed a pilot study of neoadjuvant letrozole and bevacizumab (anti-VEGF) to assess feasibility and short term efficacy in post-menopausal women with stage II/III, ER/PR positive breast cancer. Patients and Methods: Patients were treated with a neoadjuvant regimen of letrozole, 2.5 mg/day (PO) and bevacizumab 15 mg/kg every 3 weeks (IV) for a total of 24 weeks prior to surgical treatment of their breast cancer. Patients were followed for toxicity at three week intervals and tumor assessment (physical exam and tumor ultrasound) at six week intervals. Results: Twenty-five evaluable patients were treated. The regimen was well tolerated except for two patients who were taken off-study for difficult to control hypertension. Objective clinical response occurred in 17/25 patients (68%) including 16% CR and 52% PR. The four patients with clinical CR had pathologic CR in their breasts (16%) although one had residual tumor cells in axillary nodes. Two of the 17 responding patients were lost to follow-up; with a median follow-up of 50 months, no relapses have been seen in the 15 responsive patients, including 10 patients who received no adjuvant chemotherapy. Two patients with progressive disease at 9 and 16 weeks received neoadjuvant chemotherapy, surgery and radiation. One of these patients relapsed at 35 months and the other is NED at 44 months. Four patients had stable disease and all received adjuvant chemotherapy; one patient relapsed at 25 months, and the reminder are NED at 44-52 months. Overall, 2 out of 21 patients with adequate follow-up had disease reoccurrence (9.5%) at a median follow-up of 45 months. Conclusion: Combination neoadjuvant therapy with letrozole and bevacizumab was well tolerated and resulted in impressive clinical and pathologic responses. Data suggest that patients having an objective response to neoadjuvant therapy had excellent 4 year disease-free survival (100%) while relapsed occurred in 2 out of 6 patients who failed to have an objective response despite additional neoadjuvant or adjuvant chemotherapy. The Breast Cancer Translational Research Consortium has an ongoing randomized phase II trial of letrozole ± bevacizumab in this patient population.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-12-04.
Collapse
Affiliation(s)
- A Forero
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - M Saleh
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - J Galleshaw
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - C Jones
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - L Nabell
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - J Carpenter
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - C Falkson
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - H Krontiras
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - M Urist
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - K Bland
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - J De Los Santos
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - R Meredith
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - V Caterinicchia
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - W Bernreuter
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - J O'Malley
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - L Yufeng
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| | - A. LoBuglio
- University of Alabama at Birmingham; Georgia Cancer Specialists, Atlanta, GA
| |
Collapse
|
19
|
Vaughn LG, Li L, Nabell L, Rugo HS, Carey LA, Kimmick GG, Steeg PS, Miller K. A phase II study of medroxyprogesterone acetate (MPA) in patients (pts) with hormone receptor-negative (HR-) metastatic breast cancer (MBC): Translational Breast Cancer Research Consortium trial 007. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Spencer S, Carroll W, Nabell L, Meredith R, Desmond R, Magnuson J, Rosenthal E. Phase II postoperative adjuvant radiotherapy and erlotinib in patients with stage III cutaneous squamous cell carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e16007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Forero A, Saleh M, Galleshaw J, Jones C, Shah J, Percent I, Nabell L, Carpenter J, Falkson C, Krontiras H, Urist M, Bland K, De Los Santos J, Meredith R, Caterinicchia V, Bernreuter W, O'Malley J, Li Y, LoBuglio A. A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose Tumor content or expression of vascular endothelial growth factor (VEGF) is associated with impaired efficacy of anti-estrogen adjuvant therapy. We designed a pilot study of neoadjuvant letrozole and bevacizumab (anti-VEGF) to assess feasibility and short term efficacy in post-menopausal women with stage II/III, ER/PR positive breast cancer. Patients and Methods Patients were treated with a neo-adjuvant regimen of letrozole, 2.5mg/day (P.O.) and bevacizumab 15mg/kg Q3 weeks (I.V.) for a total of 24 weeks prior to surgical treatment of their breast cancer. Patients were followed for toxicity at 3 week intervals and tumor assessment (physical exam and tumor ultrasound) at 6 week intervals. PET scans were carried out prior to therapy and 6 weeks after initiation of therapy. Surgery was done 4 weeks after the last dose of bevacizumab. Results Twenty five evaluable patients were treated. The regimen was well tolerated except for 2 patients who were taken off-study for difficult to control hypertension. Objective clinical response occurred in 17/25 patients (68%) including 16% CR and 52% PR. The 4 patients with clinical CR had pathologic CR in their breasts (16%) although one had residual tumor cells in axillary nodes. 8/25 patients (32%) attained stage 0 or 1 status. PET scan response at 6 weeks correlated with clinical CR and breast pathologic CR at 24 weeks (p < 0.0036). Conclusion Combination neo-adjuvant therapy with letrozole and bevacizumab was well tolerated and resulted in impressive clinical and pathologic responses. The Breast Cancer Translational Research Consortium has an ongoing randomized phase II trial of this regimen in this patient population.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1088.
Collapse
Affiliation(s)
- A. Forero
- 1University of Alabama at Birmingham, AL,
| | - M. Saleh
- 2Georgia Cancer Specialists, GA,
| | | | - C. Jones
- 2Georgia Cancer Specialists, GA,
| | - J. Shah
- 1University of Alabama at Birmingham, AL,
| | - I. Percent
- 1University of Alabama at Birmingham, AL,
| | - L. Nabell
- 1University of Alabama at Birmingham, AL,
| | | | - C. Falkson
- 1University of Alabama at Birmingham, AL,
| | | | - M. Urist
- 1University of Alabama at Birmingham, AL,
| | - K. Bland
- 1University of Alabama at Birmingham, AL,
| | | | | | | | | | | | - Y. Li
- 1University of Alabama at Birmingham, AL,
| | | |
Collapse
|
22
|
Koya S, Li Y, McDaniel SA, LoBuglio AF, Krontiras H, Carpenter J, Nabell L, Bland K, Falkson C, Forero A. Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11566] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11566 Background: NSABP B-18 randomized women with operable breast cancer to receive chemotherapy (AC) either pre- or postoperatively; in the study there was no significant difference in disease free survival (DFS) or overall survival (OS) among patients in either group. Pathologic complete response rate (pCR) was directly proportional to DFS and OS. Dose dense adjuvant chemotherapy (ATC) has shown a statistically significant improvement in DFS and OS. Methods: We performed a single institution review of pts enrolled in a neoadjuvant trial and who received dose dense neoadjuvant chemotherapy (doxorubicin 60 mg/m2 IV Q2wks x4, paclitaxel 175 mg/m2 IV Q2wks x4, and cyclophosphamide 600 mg/m2 IV Q2wks x4) to assess response rates, safety, and DFS. Women with newly diagnosed breast cancer, T ≥ 3cm, any N, M0 were enrolled. Results: Since 02/2003, 43 pts were enrolled (mean age 47.6, range 28–64) and received dose dense chemotherapy. 41.4% of the pts were triple negative and 14.6% were Her2+ by FISH or IHC. The median follow-up is 49 months (range 8–69). Two patients dropped out without finishing therapy. Forty one pts completed dose dense chemotherapy and proceeded to surgery. 17 pts (41.4%) achieved a pCR in the breast and of those 14 pts were also negative in the axillary lymph nodes (34.1% pCR in the breast and lymph nodes). 10 of the 17 pts with pCR in the breast (8 out of the 14 pts with pCR in breast and axillary lymph nodes) were triple negative. 18 pts (43.9%) achieved PR, 3 pts (7.31%) had SD and 3 pts (7.31%) had PD. Up to November 2008, 7 pts who did not have a pCR have relapsed (4 triple negative, 1 Her2+, 1 ER/PR positive and 1 ER negative, PR positive) with a relapsed free survival rate of 85%. Hematologic toxicity consisted of grade 3 anemia in 2 patients with no grade 4 anemia, no G4 thrombocytopenia and febrile neutropenia in 2 pts. Non-hematologic grade 3 or 4 toxicity consisted of mediport thrombosis in 2 pts, hyperglycemia in 2 pts, syncope in 1 pt, neuropathy in 1 pt, and varicella zoster in 1 pt. Conclusions: Our results show that dose dense neoadjuvant chemotherapy achieves a pCR (breast + node) in about 1/3 of patients (34%) with tolerable toxicity; although the number of patients is limited, our data suggest that triple negative breast cancer seems to be the most sensitive tumor to this regimen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Koya
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - Y. Li
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - S. A. McDaniel
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - A. F. LoBuglio
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - H. Krontiras
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - J. Carpenter
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - L. Nabell
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - K. Bland
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - C. Falkson
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| | - A. Forero
- University of Alabama at Birmingham Cancer Center, Birmingham, AL
| |
Collapse
|
23
|
Falkson C, Rossman J, Nabell L, Carpenter J, Forero A, Kim Y, Saleh M. Update of a phase II trial of bevacizumab in combination with hormonal therapy to reverse acquired estrogen independence in metastatic breast cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e12027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12027 Background: Metastatic breast cancer (MBC) remains the second most common cause of cancer death in women in the US. More than 80% of breast cancers are potentially hormone responsive, but resistance eventually precludes cure. Various mechanisms of acquired hormone resistance have been postulated. Our Breast Cancer SPORE showed that increased expression of VEGF caused acquired tamoxifen resistance in MCF-7 xenografts. VEGF over-expressing MCF-7 cells displayed increased tumor growth rates and estrogen independence in vivo, and reversal of VEGF over-expression in vivo returned tumors to estrogen dependent growth. Methods: We hypothesized that adding the anti-VEGF monoclonal antibody, bevacizumab, to hormonal therapy would result in reversal of acquired hormone resistance. This multi-center, open-label, single arm phase II study was designed to evaluate safety and efficacy of this combination. Primary end point was time to progression (TTP), and the secondary endpoints were response rate and toxicity. Eligible patients had MBC and had progressed on hormonal therapy after previously responding for at least 6 months.Results: We previously reported a planned interim analysis. Results of further analysis after completion of accrual will be reported here. All 27 patients were female with median age of 63 years, and all had ER and/or PR positive MBC. Patients were continued on the same hormonal therapy to which they had become refractory, and bevacizumab (15mg/kg IV every 3 weeks) was added. Treatment was stopped early in 3 patients due to a grade 3 leg ulcer, grade 3 hypertension, and grade 3 fatigue, respectively. Overall, the therapy was tolerated well, and no treatment related deaths or thromboembolic events were seen. Stable disease was documented in 18 (66%) patients. There were no complete or partial responses. Updated median TTP will be reported. Conclusions: The combination of bevacizumab plus hormonal therapy is well tolerated in patients with metastatic breast cancer. This combination may prolong the TTP with acceptable toxicity. Further investigation utilizing this combination in metastatic breast cancer are ongoing. [Table: see text]
Collapse
Affiliation(s)
- C. Falkson
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - J. Rossman
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - L. Nabell
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - J. Carpenter
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - A. Forero
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - Y. Kim
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| | - M. Saleh
- University of Alabama, Birmingham, AL; Georgia Cancer Specialists, Georgia Cancer Specialists, GA
| |
Collapse
|
24
|
Abstract
e17522 Background: An exceptional survivor of cancer is an individual who has outlived actuarial predictions for his/her particular form of cancer or experienced a complete regression. This pilot study was designed to determine if there were any biological, psychosocial, cultural or lifestyle characteristics exceptional survivors of cancer that can be measured and transferred through interventions to other cancer patients. Methods: The sample consisted of 21 survivors of cancer who were identified by oncologists at UAB as exceptional survivors. The study gathered qualitative data through semi-structured interviews and two validated scales measuring resilience, sense of coherence. A new cancer ‘catastrophizing’ scale based on the pain catastrophizing scale (PCS) was tested for its concordance with the two validated scales. The diagnosis and treatment information on these patients was collected through a questionnaire completed by the patient's oncologist. Results: Eight oncologists referred twenty-five patients to the study. Twenty-one patients agreed to participate. A unifying theme across all patient interviews was a deep spiritual connection with a supreme being. Praying for healing, intercessory prayer, and seeking guidance through faith with respect to best treatment options were common. The patients verbalized faith in physicians and were willing to seek more experimental treatments largely due to their spirituality. In general, the survivors were highly resilient as measured by the resilience scale and had a high sense of coherence as measured by the sense of coherence scale. They were also unlikely to conceptualize the diagnosis as a ‘catastrophe’ as measured by the new cancer catastrophizing scale. Conclusions: This study provides preliminary evidence of a relationship between spirituality and exceptional survivorship. Findings suggest exceptional survivors may be more willing to participate in clinical trials than other populations of cancer patients. Future studies should prospectively follow cancer patients to ascertain the temporal nature of the association between spirituality and exceptional survivorship. No significant financial relationships to disclose.
Collapse
|
25
|
Forero-Torres A, Galleshaw J, Jones C, Percent I, Nabell L, Carpenter J, Falkson C, Krontiras H, Bland K, De Los Santos J, Saleh MN. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.625] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Falkson C, Rossman JF, Nabell L, Carpenter J, Saleh MN, O'Malley J, Forero A. A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Spencer S, Nabell L, Bonner J, Peters G, Carroll WL, Meredith R, Clemons L, Ove R. Cox-2 inhibition and chemoradiation for squamous cell carcinoma of the head and neck. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Garden A, Harris J, Vokes E, Forastiere A, Ridge J, Jones C, Horowitz E, Glisson B, Nabell L, Cooper J. Results of Radiation Therapy Oncology Group 97-03—A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck: Long-term Results and Late Toxicities. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.06.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Forero-Torres A, Percent I, Galleshaw J, Nabell L, Carpenter J, Falkson C, Jones C, Krontriras H, De Los Santos J, Saleh M. A study of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed operable breast cancer: A preliminary safety report. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11020] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11020 Background: Our preclinical studies suggest that up-regulation of tumor cell VEGF is a mechanism to subvert estrogen dependence in hormone responsive breast cancer resulting in reduced efficacy or acquired resistance; we hypothesized that the combination of Bevacizumab (an anti-VEGF MoAb) and hormonal therapy would be more effective than hormonal therapy alone for breast cancer. Methods: Post-menopausal patients with ER and/or PR positive and Her-2-neu negative operable (T2–4a-c/N 0–2/M0) breast cancer were enrolled. Patients received letrozole (2.5 mg po daily) and Bevacizumab (15 mg/kg IV q 3 wks). Patients were reevaluated every 6 wks for a total of 24 wks; patients with CR/PR/SD in the first evaluation continued in the trial; after an additional 6 weeks of therapy patients with PD or SD were taken off-study and only patients with PR/CR completed 24 weeks of therapy. Definitive surgery was performed at the discretion of the surgeon no sooner than 4 wks after the last dose of bevacizumab. Patients continued letrozole while waiting for surgery. Up to December 2006, 27 patients have been enrolled with 13 patients too early to evaluate. Results: The 14 patients off-study had a median age of 63 years (range; 56 to 79) and an ECOG score of 0 for all patients. None of the patients received therapy for breast cancer before enrollment in the trial. 11 patients were stage II and 3 patients stage III. No treatment-related severe adverse events were seen. Treatment related toxicities were: grade 3 hypertension (n=1), grade 2 hypertension (n=7), grade 2 fatigue (n=2), grade 2 joint pain (n=3), grade 2 hot flashes (n=2), grade 1 proteinuria (n=1); 2 patients were taken off-study because of uncontrolled hypertension occurring on initial infusion of bevacizumab (not evaluable for efficacy). Of the 12 patients evaluable for response, 2 patients had pCR, 8 PR and 2 PD (at 9 weeks and 16 weeks). There have been no problems with wound healing or bleeding related to surgery or progressive disease while awaiting surgery. Conclusions: Combination letrozole and bevacizumab has substantial clinical efficacy and is well tolerated. The combination therapy will be evaluated in a randomized Breast Cancer Research Consortium Trial. [Table: see text]
Collapse
Affiliation(s)
- A. Forero-Torres
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - I. Percent
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - J. Galleshaw
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - L. Nabell
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - J. Carpenter
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - C. Falkson
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - C. Jones
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - H. Krontriras
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - J. De Los Santos
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| | - M. Saleh
- University of Alabama at Birmingham, Birmingham, AL; Georgia Cancer Specialists, Atlanta, GA
| |
Collapse
|
30
|
Abstract
5582 Background: Cyclo-oxygenase 2 (COX2) inhibitors have shown promise as radio- and chemosensitizers. We conducted a phase IB/II study to evaluate the toxicity and efficacy of celecoxib, a selective COX2 inhibitor, administered concurrently with carboplatin, paclitaxel, and radiation for locally advanced or recurrent head and neck cancer. Methods: Patients with stage III/IV or recurrent squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx were eligible. Primary endpoints were toxicity, local control and survival. Patients were treated with weekly carboplatin (AUC = 2.0), paclitaxel (30 mg/m2) and concurrent radiation (70 Gy). Celecoxib (400 mg bid) was started 1 week prior to the initiation of radiotherapy and was given for a total of 2 years. In 12/04, the study closed due to concerns of cardiotoxicity with COX-2 inhibitors. Celecoxib was discontinued in all patients. The study restarted in 5/06 with the modification that celecoxib would be given only during radiation. Results: Between 12/02 and 1/06, a total of 28 patients were enrolled: 89% were male, median age was 56.5, 3 with recurrent cancer and 25 treated definitively. Five patients have been treated on the modified study. Grade 3/4 toxicities include: mucositis (35% G3), dermatitis (18% G3; 7% G4), febrile neutropenia (21% G3; 3% G4), dysphagia (57% G3), nausea/vomiting (29% G3). Thirty percent did not complete prescribed chemotherapy due to myelosuppression. Acturarial 2 year outcomes in the 20 evaluable, definitively treated patients: 65% survival, 76% local control. Conclusions: Compared to published data using carbo/taxol and RT, an unexpectantly high incident of febrile neutropenia was observed but no increase in radiation dermatitis or mucositis. Two year survival data is comparable to published data. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Prellop
- University of Alabama at Birmingham, Birmingham, AL
| | - G. Peters
- University of Alabama at Birmingham, Birmingham, AL
| | - W. Carroll
- University of Alabama at Birmingham, Birmingham, AL
| | - L. Nabell
- University of Alabama at Birmingham, Birmingham, AL
| | - S. Spencer
- University of Alabama at Birmingham, Birmingham, AL
| | - R. Ove
- University of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
31
|
Saurel C, Meredith R, Bonner JA, Peters G, Carroll W, Spencer SA, Nabell L. A phase I/II trial of induction chemotherapy followed by concomitant docetaxel with concomitant boost radiotherapy (CBR) and amifostine for advanced head and neck cancer (HNC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.15525] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15525 Background: Concomitant chemo-radiation for head and neck cancer has emerged as the optimal method of treating advanced head and neck cancers, although the acute and late toxicities can be formidable. The addition of induction chemotherapy to concomitant chemo-radiation for head and neck cancer is designed to impact the incidence of distant metastasis while delivering aggressive local treatment. This trial evaluates the tolerability and effectiveness of induction chemotherapy followed by CBR with concurrent docetaxel and subcutaneous (SC) amifostine in locally advanced squamous cell carcinoma of the head and neck (SCCHN). Methods: Patients with stage III/IV nonmetastatic SCCHN received 3 cycles of primary chemotherapy with docetaxel and cisplatin, each at 75 mg/m2. Patients then received 4 weekly doses of docetaxel at 20 mg/m2 with concurrent CBR. SC amifostine was given at a dose of 500 mg in divided doses during each day of XRT. Results: The phase I component defined the MTD of concurrent docetaxel as 20 mg/m2 for 4 cycles during CBR. 18 patients are evaluated for response. No patient developed progressive disease during primary chemotherapy. Grade 3–4 mucositis was common, but all patients completed the planned concomitant docetaxel. At 6 months after treatment, 7/18 patients still used a feeding tube, though most have had them subsequently removed. Amifostine given by SC was well tolerated; 7 patients developed transient hypotension not requiring any intervention, with grade1 dermatitis and nausea reported. 2 patients discontinued amifostine due to rash or persistent hypotension. Conclusions: Response to induction chemotherapy was greater then 75% by radiological assessment, with no patient developing distant metastasis thus far. Local control has been excellent but side effects from docetaxel and CBR have necessitated prolonged use of feeding tubes for up to 6 months. SC amifostine has been well tolerated without significant side effects. This aggressive therapy is effective treatment for locally advanced SCCHN. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Saurel
- University of Alabama at Birmingham, Birmingham, AL
| | - R. Meredith
- University of Alabama at Birmingham, Birmingham, AL
| | - J. A. Bonner
- University of Alabama at Birmingham, Birmingham, AL
| | - G. Peters
- University of Alabama at Birmingham, Birmingham, AL
| | - W. Carroll
- University of Alabama at Birmingham, Birmingham, AL
| | | | - L. Nabell
- University of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
32
|
Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G, Varterasian M, Sadis SS, Menon SS, Leopold J, Meyer MB. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3011] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Lorusso
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - S. Krishnamurthi
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - J. R. Rinehart
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - L. Nabell
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - G. Croghan
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - M. Varterasian
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - S. S. Sadis
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - S. S. Menon
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - J. Leopold
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| | - M. B. Meyer
- Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama-Birmingham, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN; Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, MI
| |
Collapse
|
33
|
Nabell L, Forero A, Urist M, Krontiras H, Dubay J, Falkson C. A phase II trial of pre-operative paclitaxel and paraplatin in women with newly diagnosed operable breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Nabell
- Univ of Alabama at Birmingham, Birmingham, AL
| | - A. Forero
- Univ of Alabama at Birmingham, Birmingham, AL
| | - M. Urist
- Univ of Alabama at Birmingham, Birmingham, AL
| | | | - J. Dubay
- Univ of Alabama at Birmingham, Birmingham, AL
| | - C. Falkson
- Univ of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
34
|
Menon SS, Whitfield LR, Sadis S, Meyer MB, Leopold J, Lorusso PM, Krishnamurthi S, Rinehart JR, Nabell L, Croghan G. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3066] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. S. Menon
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - L. R. Whitfield
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - S. Sadis
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - M. B. Meyer
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - J. Leopold
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - P. M. Lorusso
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - S. Krishnamurthi
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - J. R. Rinehart
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - L. Nabell
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| | - G. Croghan
- Pfizer Global Research & Development, Michigan Laboratories, Ann Arbor, MI; Wayne State Univ, Detroit, MI; Case Comprehensive Cancer Ctr, Cleveland, OH; Univ of Alabama, Birmingham, AL; Mayo Clinic & Fdn, Rochester, MN
| |
Collapse
|
35
|
Prellop P, Ove R, Meredith R, Bonner J, Peters G, Carroll W, Spencer S, Nabell L. A phase I/II trial of induction chemotherapy followed by concomitant docetaxel with concomitant boost radiotherapy (CBR) for cancer of the head and neck. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Prellop
- Univ of Alabama at Birmingham, Birmingham, AL
| | - R. Ove
- Univ of Alabama at Birmingham, Birmingham, AL
| | - R. Meredith
- Univ of Alabama at Birmingham, Birmingham, AL
| | - J. Bonner
- Univ of Alabama at Birmingham, Birmingham, AL
| | - G. Peters
- Univ of Alabama at Birmingham, Birmingham, AL
| | - W. Carroll
- Univ of Alabama at Birmingham, Birmingham, AL
| | - S. Spencer
- Univ of Alabama at Birmingham, Birmingham, AL
| | - L. Nabell
- Univ of Alabama at Birmingham, Birmingham, AL
| |
Collapse
|
36
|
Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2004; 22:2856-64. [PMID: 15254053 DOI: 10.1200/jco.2004.12.012] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
PURPOSE To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck. PATIENTS AND METHODS The Radiation Therapy Oncology Group developed this three-arm randomized phase II trial. Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible. Each of three arms proposed a radiation schedule of 70 Gy in 35 fractions. Patients on arm 1 were to receive cisplatin 10 mg/m(2) daily and fluorouracil (FU) 400 mg/m(2) continuous infusion (CI) daily for the final 10 days of treatment. Treatment on arm 2 consisted of hydroxyurea 1 g every 12 hours and FU 800 mg/m(2)/d CI delivered with each fraction of radiation. Arm 3 patients were to receive weekly paclitaxel 30 mg/m(2) and cisplatin 20 mg/m(2). Patients randomly assigned to arms 1 and 3 were to receive their treatments every week; patients on arm 2 were to receive their therapy every other week. RESULTS Between 1997 and 1999, 241 patients were entered onto study; 231 were analyzable. Ninety-two percent, 79%, and 83% of patients on arms 1, 2, and 3, respectively, were able to complete their radiation as planned or with an acceptable variation. Fewer than 10% of patients had unacceptable deviations or incomplete chemotherapy in the three arms. Estimated 2-year disease-free and overall survival rates were 38.2% and 57.4% for arm 1, 48.6% and 69.4% for arm 2, and 51.3% and 66.6% for arm 3. CONCLUSION We have demonstrated that three different approaches of concurrent multiagent chemotherapy and radiation were feasible and could be delivered to patients in a multi-institutional setting with high compliance rates.
Collapse
Affiliation(s)
- A S Garden
- Department of Radiation Oncology, Unit 97, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
The addition of interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to hormone-dependent cells induces tyrosine phosphorylation of Janus protein kinase 2 (Jak2) and activates its in vitro kinase activity. To explore the role of Jak2 in IL-3/GM-CSF-mediated signal transduction, we constructed a CD16/CD7/Jak2 (CD16/Jak2) fusion gene containing the external domain of CD16 and the entire Jak2 molecule and expressed this fusion protein using a recombinant vaccinia virus. The clustering of CD16/Jak2 fusion protein by cross-linking with an anti-CD16 antibody induced autophosphorylation of the fusion protein but did not induce the phosphorylation of either the endogenous Jak2 or the beta chain. Cross-linking of CD16/Jak2 stimulates the tyrosine phosphorylation of a large group of proteins that are also phosphorylated after the addition of IL-3 or GM-CSF and include proteins of 145, 97, 67, 52, and 42 kDa. Closer analysis demonstrated that the CD16/Jak2 phosphorylates Shc, a 52-kDa protein, and the 145-kDa protein associated tightly with Shc, as well as mitogen-associated protein kinase (pp42). Electrophoretic mobility shift assays demonstrate that CD16/Jak2 activates the ability of signal transduction and activation of transcription (STAT) proteins to bind to an interferon-gamma-activated sequence oligonucleotide in a manner similar to that seen after IL-3 treatment. Cross-linking of the CD16/Jak2 protein stimulated increases in c-fos and junB similar to IL-3 but did not cause major changes in the levels of the c-myc message, which normally increases after IL-3 treatment. Thus, a transmembrane CD16/Jak2 fusion is capable of activating protein phosphorylation and mRNA transcription in a manner similar but not identical to hematopoietic growth factors.
Collapse
MESH Headings
- Animals
- Antigens, CD/genetics
- Antigens, CD/metabolism
- Antigens, CD7
- Antigens, Differentiation, T-Lymphocyte/genetics
- Antigens, Differentiation, T-Lymphocyte/metabolism
- B-Lymphocytes
- Base Sequence
- Calcium-Calmodulin-Dependent Protein Kinases/metabolism
- Cell Line
- Cross-Linking Reagents
- Enzyme Activation
- Hematopoietic Stem Cells
- Janus Kinase 2
- Mice
- Molecular Sequence Data
- Phosphoproteins/biosynthesis
- Phosphorylation
- Protein-Tyrosine Kinases/genetics
- Protein-Tyrosine Kinases/metabolism
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins c-myc/biosynthesis
- Receptors, IgG/genetics
- Receptors, IgG/metabolism
- Recombinant Fusion Proteins/metabolism
- Signal Transduction
- Transcription, Genetic
Collapse
Affiliation(s)
- I Sakai
- Department of Medicine, University of Alabama, Birmingham 35223
| | | | | |
Collapse
|
38
|
Zachary JM, Cleveland G, Kwock L, Lawrence T, Weissman RM, Nabell L, Fried FA, Staab EV, Risinger MA, Lin S. Actin filament organization of the Dunning R3327 rat prostatic adenocarcinoma system: correlation with metastatic potential. Cancer Res 1986; 46:926-32. [PMID: 3940653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Recently, Volk, Geiger, and Raz (Cancer Res., 44: 811-824, 1984) addressed the question of whether variations in actin organization in clones of the murine K-1735 melanoma tumor correlated with their metastatic capability. Using immunofluorescence techniques, they found that clones which had a more ordered actin network were less metastatic, whereas clones having a diffuse actin staining pattern were more metastatic. Similarly, we have found that in the Dunning rat R3327 prostatic adenocarcinoma tumor system, the non-metastatic (less than 0.1%) H-prostatic tumor cell line has a prominent network of actin filament bundles, whereas the highly metastatic (greater than 90%) MatLyLu cell line has a diffuse actin staining pattern. In the low-metastatic (less than 10%) AT1 cell line an intermediate actin organization between H and MatLyLu was observed. Analysis of cell extracts from H- and MatLyLu-cells revealed differences in the level of activity of cellular proteins which affect actin filament assembly and structure in a manner similar to that of the cytochalasins, fungal metabolites which bind with high affinity to the fast-growing end of actin filaments. Extracts of MatLyLu were significantly more effective than those of H-cells in decreasing the extent of actin filament network formation and in inhibiting the rate of filament assembly by blocking monomer addition onto the fast-growing end. Measurements of spin-lattice nuclear magnetic resonance water proton relaxation times (T1) were made in surgically removed tumor tissue from four sublines (H, AT1, MatLyLu, and MatLu) of the Dunning R3327 tumor system. The highly metastatic cell lines had significantly longer water proton T1 relaxation times than did the lines with low metastatic potential. These differences in T1 may reflect the observed alterations in organization of actin filaments within these various sublines of the Dunning R3327 prostatic adenocarcinoma tumor system.
Collapse
|